NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
Grupo Espanol de Tumores Neuroendocrinos
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
IRCCS San Raffaele
Central European Society for Anticancer Drug Research